Free Daily Headlines :

  • COVID-19
  • Money
  • Election 2020
  • Politics
  • Education
  • Health
  • Justice
  • More
    • Environment
    • Economic Development
    • Gaming
    • Investigations
    • Social Services
    • TRANSPORTATION
  • Opinion
    • CT Viewpoints
    • CT Artpoints
DONATE
Reflecting Connecticut’s Reality.
    COVID-19
    Money
    Election 2020
    Politics
    Education
    Health
    Justice
    More
    Environment
    Economic Development
    Gaming
    Investigations
    Social Services
    TRANSPORTATION
    Opinion
    CT Viewpoints
    CT Artpoints

LET�S GET SOCIAL

Show your love for great stories and out standing journalism

Lembo helps Dems in D.C. sharpen attack on high drug costs

  • Health
  • by Ana Radelat
  • December 2, 2015
  • View as "Clean Read" "Exit Clean Read"
State Comptroller Kevin Lembo

Arielle Levin Becker :: CTMirror.org File Photo

State Comptroller Kevin Lembo

Washington – Connecticut Comptroller Kevin Lembo has joined a growing Democratic attack on high drug prices, an issue expected to be at the center of many Democratic election campaigns next year.

He was supposed to be there in person, but fog and rain grounded his plane and kept him from testifying at a Capitol Hill hearing on drug pricing Wednesday. Lembo submitted written testimony instead.

He said the reasons drug prices are rising include market consolidation, new pricing models and “outright profiteering.”

“Projections indicate no future relief as pharmacy costs are expected to continue to rise at an exorbitant rate in the coming years. Meanwhile, pharmaceutical companies are recording historic profits,” Lembo said. “These drugs – lifesaving, life-changing medications – are not yachts, private jets, and other material icons of wealth reserved only for the privileged few.”

Wednesday’s hearing was held by the Democratic Steering Committee, a maneuver that allows House Democrats to convene a hearing in a chamber controlled by Republicans.

Rep. Rosa DeLauro, D-3rd District, is a member of the steering committee. She is also a member of a new Affordable Drug Pricing Task Force created by House Democrats.

At Wednesday’s hearing, DeLauro lambasted drug companies like Turing Pharmaceuticals, which hiked the price of Daraprim — a 62-year-old drug  that treats rare parasitic infections — from $13.50 to $750 a pill.

DeLauro also cited the drug pricing practices of Valeant Pharmaceuticals and of Gilead Sciences, a  drug company that charges $1,000 a pill for a hepatitis C treatment.

“Every day we see the threat that spiraling drug costs pose to Medicare, Medicaid and HIV treatments,” DeLauro said.

Gilead Sciences did not have an immediate response.

PhRMA, the trade association for the nation’s drug companies, said those concerned  about the cost of prescription drugs should look at spending across the health care system “and not just at the share of spending that goes toward life-changing medicines.”

“New medicines are transforming care for patients fighting debilitating diseases like cancer, hepatitis c, high cholesterol and more,” said PhRMA spokeswoman Holly Campbell. “At the same time, the share of spending on medicines has been consistent for more than 50 years.” Campbell said drug companies have been able to hold prices down “due to a competitive marketplace for medicines where generic utilization rates are high and robust competition among brand name medicines.”

She also said there should be a greater focus on the high cost sharing required by many insurance companies and restrictions on access to certain drugs by insurers that make certain medicines unaffordable.

Democrats like Hillary Clinton, her party’s frontrunner for the White House, have seized on the issue of the high cost of drugs, which she says is driving health care costs up and putting needed drugs out to the reach of some patients, even under the Affordable Care Act.

Health insurers have also redoubled their efforts to press Congress to do something about the high cost of drugs.

After 18 months of investigation, the Senate Finance Committee issued a report Tuesday that said Gilead Sciences knew its $1,000-a-pill  price would put hepatitis C treatment out of reach of many patients and cause “extraordinary problems” for government health programs.

“This investigation underscores the disconnect between drug company rhetoric and reality,” said America’s Health Insurance Plans President Marilyn Tavenner. “It’s time for drug companies to be held to the same access and affordability standards that apply to the rest of the health system, and that starts with greater transparency in drug pricing.”

In his written testimony, Lembo said that as the state comptroller, he  administers health benefits for more than  200,000 state and municipal employees, retirees and their dependents.

“The sharp rise in pharmacy costs comes at a time when we are seeing great success in limiting medical spending by promoting preventive care and chronic disease management through the state’s Health Enhancement Program,” Lembo said. “The drastic increases in pharmacy costs are undermining our medical cost savings.”

Brian Lehman, head of the pharmacy benefits program of the Ohio Public Employees Retirement System; Jeremy Green, a professor of medicine at Johns Hopkins University; and Lynn Quincy of Consumers Union testified on the impacts of high-cost medicine.

But it’s not clear what steps, if any, Congress can take to slow the rise in pharmaceutical prices. House Minority Leader Nancy Pelosi, D-Calif., backs legislation that would repeal the ban preventing Medicare from negotiating directly with pharmaceutical companies.

The American Medical Association recently decided to lobby Congress to ban  “direct-to-consumer” drug advertising that urges people to “ask their doctor” if a certain drug  is right for them.

AMA Board Chair-elect Patrice A. Harris said support for an ad ban “reflects concerns among physicians about the negative impact of commercially driven promotions, and the role that marketing costs play in fueling escalating drug prices.”

Sign up for CT Mirror's free daily news summary.

Free to Read. Not Free to Produce.

The Connecticut Mirror is a nonprofit newsroom. 90% of our revenue comes from people like you. If you value our reporting please consider making a donation. You'll enjoy reading CT Mirror even more knowing you helped make it happen.

YES, I'LL DONATE TODAY

ABOUT THE AUTHOR

Ana Radelat Ana has written about politics and policy in Washington, D.C.. for Gannett, Thompson Reuters and UPI. She was a special correspondent for the Miami Herald, and a regular contributor to The New York TImes, Advertising Age and several other publications. She has also worked in broadcast journalism, for CNN and several local NPR stations. She is a graduate of the University of Maryland School of Journalism.

SEE WHAT READERS SAID

RELATED STORIES
Nursing home residents are receiving the COVID vaccination at a higher rate than their caretakers
by Dave Altimari and Jenna Carlesso

Providers attributed workers' reluctance to a variety of issues, from concerns about fertility to uncertainty about the side effects.

Legislative leaders support extension of Lamont’s emergency powers during COVID
by Jacqueline Rabe Thomas

The governor's emergency powers expire Feb. 9 unless he asks lawmakers for an extension within 72 hours of that date.

‘No one took us seriously:’ Black cops warned about racist Capitol Police officers for years
by Joshua Kaplan and Joaquin Sapien | ProPublica

While many officers were filmed fighting off Capitol rioters, at least 12 others are under investigation for possibly assisting them.

Donald Trump built a national debt so big (even before the pandemic) that it’ll weigh down the economy for years
by Allan Sloan and Cezary Podkul | ProPublica

The national debt has risen by almost $7.8 trillion during President Trump’s time in office.

For some transgender people, pandemic paves path to transition
by Carol Leonetti Dannhauser | C-HIT.ORG

The COVID-19 pandemic has given many transgender individuals the incentive to begin gender-affirming hormone therapy.

Support Our Work

Show your love for great stories and outstanding journalism.

$
Select One
  • Monthly
  • Yearly
  • Once
Artpoint painter
CT ViewpointsCT Artpoints
Opinion The change in leadership must not lead to complacency
by Jenna Van Donselaar

We are beginning 2021, and most people are far done with election talk. Sure, the polls are closed, and the results are in, and it is time to move on. I am weary from the hours I spent texting voters this fall, and I’d like to think all my efforts were worth it. But the work is far from done.

Opinion Treason is in the air
by David Holahan

Abraham Lincoln had been elected but had yet to assume the presidency when southern states started seceding from the Union in the months before his March 4, 1961 inauguration. Four others would follow that spring. American soldiers —like Robert E. Lee, who had taken an oath of loyalty to the nation that he had served since 1825— defected to the Confederacy. By joining the rebellion Lee and fellow travellers became, in effect, traitors.

Opinion Trump’s reaction to defeat further confirms urgency for school focus on social emotional skills 
by Sandra M. Chafouleas 

Imagine what would happen if a preschooler didn’t “use their words” when they got upset about sharing, instead stomping around yelling while adults simply observed in silence. Think about what the school climate would feel like if a student punched another during recess while others watched without seeking help.  Now consider the actions – and inactions – by Trump Jan. 6 as the electoral vote counts occurred at the U.S. Capitol.

Opinion Is Trump leading a cult?
by Elena Sada

My experience as a former cult member and researcher in the field of Social Sciences earned me the ability to identify narcissism and cultish tendencies. Furthermore, as a former  New York City resident who kept abreast of interviews with the city’s apparent “movers and shakers,” I often questioned Trump’s qualifications as a leader, let alone as national presidential leader.

Artwork Grand guidance
by Anne:Gogh

In a world of systemic oppression aimed towards those of darker skintones – representation matters. We are more than our equity elusive environments, more than numbers in a prison and much more than victims of societal dispositions. This piece depicts a melanated young man draped in a cape ascending high above multiple forms of oppression. […]

Artwork Shea
by Anthony Valentine

Shea is a story about race and social inequalities that plague America. It is a narrative that prompts the question, “Do you know what it’s like to wake up in new skin?”

Artwork The Declaration of Human Rights
by Andres Chaparro

Through my artwork I strive to create an example of ideas that reflect my desire to raise social consciousness, and cultural awareness. Jazz music is the catalyst to all my work, and plays a major influence in each piece of work.”

Artwork ‘A thing of beauty. Destroy it forever’
by Richard DiCarlo | Derby

During times like these it’s often fun to revisit something familiar and approach things with a different slant. I have been taking some Pop culture and Art masterpieces and applying the vintage 1960’s and 70’s classic figures (Fisher Price, little people) to the make an amusing pieces. Here is my homage to Fisher -Price, Yellow […]

Twitter Feed
A Twitter List by CTMirror

Engage

  • Reflections Tickets & Sponsorships
  • Events
  • Donate
  • Newsletter Sign-Up
  • Submit to Viewpoints
  • Submit to ArtPoints
  • Economic Indicator Dashboard
  • Speaking Engagements
  • Commenting Guidelines
  • Legal Notices
  • Contact Us

About

  • About CT Mirror
  • Announcements
  • Board
  • Staff
  • Sponsors and Funders
  • Donors
  • Friends of CT Mirror
  • History
  • Financial
  • Policies
  • Strategic Plan

Opportunity

  • Advertising and Sponsorship
  • Speaking Engagements
  • Use of Photography
  • Work for Us

Go Deeper

  • Steady Habits Podcast
  • Economic Indicator Dashboard
  • Five Things

The Connecticut News Project, Inc. 1049 Asylum Avenue, Hartford, CT 06105. Phone: 860-218-6380

© Copyright 2021, The Connecticut News Project. All Rights Reserved. Website by Web Publisher PRO